Reports Q3 revenue $213M, consensus $210.73M. “During the third quarter of 2024, we grew revenue by 11%, compared to the third quarter of ...

Highlights Third quarter revenue grew 11% year-over-year to $213 million, driven by Pharmacogenomics (34%) and Prenatal (10%) ...

Myriad (MYGN) delivered earnings and revenue surprises of 200% and 1.66%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

(RTTNews) - Below are the earnings highlights for Myriad Genetics Inc. (MYGN): Earnings: -$22.1 million in Q3 vs. -$61.3 million in the same period last year. EPS: -$0.24 in Q3 vs. -$0.75 in the same ...

Myriad Genetics stock plunges after UnitedHealth Group announces they will no longer cover genetic tests for mental health ...

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Myriad Genetics Inc. (MYGN) on Thursday reported a loss of $22.1 million in its third quarter. On a per-share basis, the Salt Lake City-based company said ...

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. (“Myriad” or “the Company”) ...

Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy.

On Friday, Myriad Genetics, Inc. (MYGN) stock saw a decline, ending the day at $17.99 which represents a decrease of $-3.97 or -18.08% from the prior close of $21.96. The stock opened at $20.04 and ...

On Monday, TD Cowen maintained a Hold rating for Myriad Genetics (NASDAQ:MYGN) shares with a steady price target of $30.00. This decision comes in the wake of UnitedHealthcare's (UNH) recent ...

Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) has earned a consensus recommendation of “Hold” from the twelve analysts that are currently covering the stock, Marketbeat.com reports.